Loading insider details...
Beta
Latest Form 4 (Jun 8, 2026): Exercise/Conversion of 11,580 ACRS shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 8, 2026 | Aclaris Therapeutics, Inc. (ACRS) | Exercise/Conversion | 11,580 | n/a |
| May 21, 2026 | Passage BIO, Inc. (PASG) | Grant/Award | 10,539 | n/a |
| Dec 12, 2025 | Merus N.V. (MRUS) | Disposition to Issuer | 13,193 | n/a |
| Jun 9, 2025 | Aclaris Therapeutics, Inc. (ACRS) | Exercise/Conversion | 4,793 | n/a |
| May 30, 2025 | Passage BIO, Inc. (PASG) | Grant/Award | 201,857 | n/a |
| May 27, 2025 | Merus N.V. (MRUS) | Grant/Award | 13,193 | n/a |
| Jun 10, 2024 | Aclaris Therapeutics, Inc. (ACRS) | Grant/Award | 15,750 | n/a |
| Jun 4, 2024 | Aclaris Therapeutics, Inc. (ACRS) | Exercise/Conversion | 4,660 | n/a |
| May 23, 2024 | Passage BIO, Inc. (PASG) | Grant/Award | 47,693 | n/a |
| May 9, 2024 | Merus N.V. (MRUS) | Grant/Award | 8,844 | n/a |